<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01524978</url>
  </required_header>
  <id_info>
    <org_study_id>MO28072</org_study_id>
    <secondary_id>2011-004426-10</secondary_id>
    <nct_id>NCT01524978</nct_id>
  </id_info>
  <brief_title>A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers</brief_title>
  <official_title>An Open-label, Phase II Study of Vemurafenib in Patients With BRAF V600 Mutation-positive Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open-label, multi-center study will assess the efficacy and safety of vemurafenib in
      participants with BRAF V600 mutation-positive cancers (solid tumors and multiple myeloma,
      except melanoma and papillary thyroid cancer) and for whom vemurafenib is deemed the best
      treatment option in the opinion of the investigator. Participants will receive twice daily
      oral doses of 960 mg vemurafenib until disease progression, unacceptable toxicity, or
      withdrawal of consent. The safety and efficacy of vemurafenib in combination with cetuximab
      in a subset of participants with colorectal cancer will also be assessed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 12, 2012</start_date>
  <completion_date type="Actual">October 28, 2016</completion_date>
  <primary_completion_date type="Actual">October 28, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmed Best Overall Response Rate (BORR)</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>Confirmed BORR: percentage of participants with an objective response (OR) (complete response [CR], partial response [PR], stringent CR [sCR] or very good PR [VGPR]) on 2 occasions &gt;/= 4 weeks apart as assessed by the Investigator using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. or International Myeloma Working Group (IMWG) criteria. RECIST v1.1: CR: disappearance of all target lesions; PR: &gt;/= 30% decrease in the sum of diameters of target lesions. IMWG: CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and &lt;/= 5% plasma cells in bone marrow; PR: &gt;/= 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by &gt;/= 90% or to &lt;200 mg per 24 hours. VGPR: serum and urine M-protein detectable by immunofixation but not on electrophoresis or &gt;/= 90% reduction in serum M-protein plus urine M-protein level &lt; 100 mg per 24 hour; sCR: CR plus normal free light chain (FLC) ratio and no clonal cells in bone marrow.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Confirmed Clinical Benefit</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>Included were participants with confirmed PR or CR or Stable Disease (SD) that had lasted at least 6 months according to RECIST v1.1 or confirmed CR, PR, VGPR, sCR or SD for at least 6 months according to IMWG criteria. RECIST v1.1: PR: &gt;/= 30% decrease in the sum of diameters of target lesions; CR: disappearance of all target lesions; SD: not meeting criteria for CR, PR or progressive disease (PD). IMWG: CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and &lt;/= 5% plasma cells in bone marrow; PR: &gt;/= 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by &gt;/= 90% or to &lt;200 mg per 24 hours. VGPR: serum and urine M-protein detectable by immunofixation but not on electrophoresis or &gt;/= 90% reduction in serum M-protein plus urine M-protein level &lt; 100 mg per 24 hour; sCR: CR plus normal FLC ratio and no clonal cells in bone marrow; SD: not meeting criteria for CR, VGPR, PR or PD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>ORR: percentage of participants with an objective response (OR) (CR, PR, sCR or VGPR) on 2 occasions &gt;/= 4 weeks apart as assessed by the Investigator using RECIST v1.1. or IMWG criteria. RECIST v1.1: CR: disappearance of all target lesions; PR: &gt;/= 30% decrease in the sum of diameters of target lesions. IMWG: CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and &lt;/= 5% plasma cells in bone marrow; PR: &gt;/= 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by &gt;/= 90% or to &lt;200 mg per 24 hours. VGPR: serum and urine M-protein detectable by immunofixation but not on electrophoresis or &gt;/= 90% reduction in serum M-protein plus urine M-protein level &lt; 100 mg per 24 hour; sCR: CR plus normal FLC ratio and no clonal cells in bone marrow.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>DOR was defined as the period from the date of initial PR or CR for solid tumors according to RECISTv1.1 and CR, PR, VGPR or sCR for multiple myeloma according to IMWG criteria, until the date of PD or death from any cause. RECIST v1.1: PD: At least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. IMWG: PD: increase of &gt;/= 25% from lowest response value in serum or urine M-protein or bone marrow plasma cell percentage or development of new or increase in size of bone lesions or soft tissue plasmacytomas.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>Time to response was defined as the time from the first day of study treatment to the date of first CR, or PR for solid tumors according to RECISTv1.1 and CR, PR, VGPR or sCR for multiple myeloma according to IMWG criteria. RECIST v1.1: CR: disappearance of all target lesions; PR: at least a 30% decrease in the sum of diameters of target lesions. IMWG criteria: CR: negative immunofixation on serum and urine and disappearance of any soft tissue plasmacytomas and &lt;/= 5% plasma cells in bone marrow; PR: &gt;/= 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by &gt;/= 90% or to &lt; 200 mg per 24 hours. VGPR: serum and urine M-protein detectable by immunofixation but not on electrophoresis or &gt;/= 90% reduction in serum M-protein plus urine M-protein level &lt; 100 mg per 24 hour; sCR: CR plus normal FLC ratio and no clonal cells in bone marrow.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Tumor Progression (TTP)</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>TTP was defined as time from the first day of study treatment to the first occurrence of progressive disease (PD). RECIST v1.1: PD: at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. IMWG: PD: increase of &gt;/= 25% from lowest response value in serum or urine M-protein or bone marrow plasma cell percentage or development of new or increase in size of bone lesions or soft tissue plasmacytomas.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>PFS was defined as the time from the first day of study treatment, until the first documented PD or death from any cause, whichever occurs first. RECIST v1.1: PD: at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. IMWG criteria: PD: increase of &gt;/= 25% from lowest response value in serum or urine M-protein or bone marrow plasma cell percentage or development of new or increase in size of bone lesions or soft tissue plasmacytomas.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>OS was defined as time between the first day of study treatment and date of death of any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Tolerated Dose for Vemurafenib in Combination With Cetuximab</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>Cohort 3b included participants with colorectal cancer treated with escalating doses of vemurafenib and cetuximab. The escalating doses were as follows: Dose Level 1: 720 milligrams (mg) of vemurafenib orally twice daily starting on Day 2 of Cycle 1 and 300 milligrams per square meter (mg/m^2) loading dose of cetuximab by infusion and then 200 mg/m^2 weekly; Dose Level 2: 720 mg of vemurafenib twice daily starting on Day 2 of Cycle 1 and 400 mg/m^2 loading dose of cetuximab and then 250 mg/m^2 weekly; Dose Level 3: 960 mg of vemurafenib twice daily starting on Day 2 of Cycle 1 and 400 mg/m^2 loading dose of cetuximab and then 250 mg/m^2 weekly. Reported here are the maximum tolerated doses for each vemurafenib and cetuximab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Dose-limiting Toxicities of Vemurafenib in Combination With Cetuximab</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Cohort 3b included participants with colorectal cancer treated with escalating doses of vemurafenib and cetuximab. The escalating doses were as follows: Dose Level 1: 720 milligrams (mg) of vemurafenib orally twice daily starting on Day 2 of Cycle 1 and 300 milligrams per square meter (mg/m^2) loading dose of cetuximab by infusion and then 200 mg/m^2 weekly; Dose Level 2: 720 mg of vemurafenib twice daily starting on Day 2 of Cycle 1 and 400 mg/m^2 loading dose of cetuximab and then 250 mg/m^2 weekly; Dose Level 3: 960 mg of vemurafenib twice daily starting on Day 2 of Cycle 1 and 400 mg/m^2 loading dose of cetuximab and then 250 mg/m^2 weekly. Reported here are type and number of dose limited toxicities observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Percentage of Participants With Adverse Event</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">208</enrollment>
  <condition>Multiple Myeloma, Neoplasms</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - vemurafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with NSCLC will be treated with vemurafenib monotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Ovarian Cancer - vemurafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with ovarian cancer will be treated with vemurafenib monotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3a: Colorectal Cancer - vemurafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with colorectal cancer will be treated with vemurafenib monotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3b: Colorectal Cancer - vemurafenib + cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with colorectal cancer will be treated with vemurafenib and cetuximab combination therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: Cholangiocarcinoma - vemurafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with cholangiocarcinoma will be treated with vemurafenib monotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6: Multiple Myeloma - vemurafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with multiple myeloma will be treated with vemurafenib monotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7: Other Solid Tumors - vemurafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with Erdheim-Chester disease (ECD), Langerhans cell histiocytosis (LCH), anaplastic thyroid cancer, advanced stage astrocytoma, early stage astrocytoma and other BRAF V600-positive tumors will be treated with vemurafenib monotherapy. Subcohorts will be analyzed separately if 7 or more participants are enrolled for each indication.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <description>Escalating doses administered on Day 1 and then once weekly by intravenous infusion.</description>
    <arm_group_label>Cohort 3b: Colorectal Cancer - vemurafenib + cetuximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vemurafenib</intervention_name>
    <description>Escalating doses given orally twice a day starting on Day 2</description>
    <arm_group_label>Cohort 3b: Colorectal Cancer - vemurafenib + cetuximab</arm_group_label>
    <other_name>Zelboraf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vemurafenib</intervention_name>
    <description>960 mg vemurafenib orally twice a day until disease progression, unacceptable toxicity, or withdrawal of consent.</description>
    <arm_group_label>Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - vemurafenib</arm_group_label>
    <arm_group_label>Cohort 2: Ovarian Cancer - vemurafenib</arm_group_label>
    <arm_group_label>Cohort 3a: Colorectal Cancer - vemurafenib</arm_group_label>
    <arm_group_label>Cohort 4: Cholangiocarcinoma - vemurafenib</arm_group_label>
    <arm_group_label>Cohort 6: Multiple Myeloma - vemurafenib</arm_group_label>
    <arm_group_label>Cohort 7: Other Solid Tumors - vemurafenib</arm_group_label>
    <other_name>Zelboraf</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

          -  Must have recovered from all side effects of their most recent systemic or local
             treatment

          -  Adequate hematological, renal and liver function

        For solid tumors only:

          -  Histologically confirmed cancers (excluding melanoma and papillary thyroid cancer)
             with a BRAF V600 mutation and that are resistant to standard therapy or for which
             standard or curative therapy does not exist

          -  Measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST)

        For multiple myeloma only:

          -  Confirmed diagnosis of multiple myeloma with a BRAF V600 mutation

          -  Must have received at least one prior systemic therapy for the treatment of multiple
             myeloma

          -  Treated with local radiotherapy

          -  Must have relapsed and/or refractory multiple myeloma with measurable disease

        Exclusion Criteria:

          -  Melanoma, papillary thyroid cancer or hematological malignancies (with the exception
             of multiple myeloma)

          -  Uncontrolled concurrent malignancy

          -  Multiple myeloma: solitary bone or solitary extramedullary plasmacytoma as the only
             evidence of plasma cell dyscrasia

          -  Active or untreated central nervous system (CNS) metastases

          -  History of or known carcinomatous meningitis

          -  Concurrent administration of any anti-cancer therapies other than those administered
             in this study

          -  Other severe, acute, or chronic medical or psychiatric condition or laboratory
             abnormality that would, in the investigator's opinion, contraindicate participation in
             this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Oncology</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers, LLP</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital;Oncology</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yakima Valley Memorial Hospital/North Star Lodge</name>
      <address>
        <city>Yakima</city>
        <state>Washington</state>
        <zip>98902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Cancer Hospital</name>
      <address>
        <city>Tianjin</city>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie; Oncologie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Francois Baclesse; Oncologie</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard; Departement Oncologie Medicale</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes; Oncologie Medicale 1</name>
      <address>
        <city>Marseille Cedex 09</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Rene Gauducheau</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud; Departement Oncologie Medicale</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy; Sitep</name>
      <address>
        <city>VILLEJUIF Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen; Innere Klinik und Poliklinik für Tumorforschung</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik der Uni zu Koeln; Klinik I für Innere Medizin; Onkologie</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Mannheim, Tagestherapiezentrum, Interdisziplinäres Tumorzentrum</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Univ. Central de Asturias; Servicio de Oncologia</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar; Servicio de Oncologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Univ Vall d'Hebron; Servicio de Oncologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañon; Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Jimenez Diaz; Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Integral Oncologico Clara Campal (CIOCC); Dirección Médica</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Salamanca; Servicio de Oncologia</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden Hospital; Dept of Medicine</name>
      <address>
        <city>London</city>
        <zip>SW3 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.trialreach.com/s/120326</url>
    <description>Trialreach Entry</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2012</study_first_submitted>
  <study_first_submitted_qc>January 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2012</study_first_posted>
  <results_first_submitted>August 22, 2017</results_first_submitted>
  <results_first_submitted_qc>October 17, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">November 20, 2017</results_first_posted>
  <last_update_submitted>October 17, 2017</last_update_submitted>
  <last_update_submitted_qc>October 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vemurafenib</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>One participant with breast cancer was screened shortly after Cohort 5 (Breast Cancer) had been closed. This participant was allowed to enter the study in Cohort 7: Other BRAF V600-positive tumors. For analysis purposes Cohort 7 was split into sub-cohorts for indications with sufficient participants.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - Vemurafenib</title>
          <description>Participants with NSCLC were treated with vemurafenib monotherapy.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2: Ovarian Cancer - Vemurafenib</title>
          <description>Participants with ovarian cancer were treated with vemurafenib monotherapy.</description>
        </group>
        <group group_id="P3">
          <title>Cohort 3a: Colorectal Cancer - Vemurafenib</title>
          <description>Participants with colorectal cancer were treated with vemurafenib monotherapy.</description>
        </group>
        <group group_id="P4">
          <title>Cohort 3b: Colorectal Cancer - Vemurafenib + Cetuximab</title>
          <description>Participants with colorectal cancer were treated with vemurafenib and cetuximab combination therapy.</description>
        </group>
        <group group_id="P5">
          <title>Cohort 4: Cholangiocarcinoma - Vemurafenib</title>
          <description>Participants with cholangiocarcinoma were treated with vemurafenib monotherapy.</description>
        </group>
        <group group_id="P6">
          <title>Cohort 6: Multiple Myeloma - Vemurafenib</title>
          <description>Participants with multiple myeloma were treated with vemurafenib monotherapy.</description>
        </group>
        <group group_id="P7">
          <title>Cohort 7a: ECD/LCH - Vemurafenib</title>
          <description>Participants with Erdheim-Chester disease (ECD) or Langerhans cell histiocytosis (LCH) were treated with vemurafenib monotherapy.</description>
        </group>
        <group group_id="P8">
          <title>Cohort 7b: Anaplastic Thyroid Cancer - Vemurafenib</title>
          <description>Participants with anaplastic thyroid cancer were treated with vemurafenib monotherapy.</description>
        </group>
        <group group_id="P9">
          <title>Cohort 7c: Advanced Stage Astrocytoma - Vemurafenib</title>
          <description>Participants with advanced stage astrocytoma were treated with vemurafenib monotherapy.</description>
        </group>
        <group group_id="P10">
          <title>Cohort 7d: Early Stage Astrocytoma - Vemurafenib</title>
          <description>Participants with early stage astrocytoma were treated with vemurafenib monotherapy.</description>
        </group>
        <group group_id="P11">
          <title>Cohort 7: Other BRAF V600-positive Tumors - Vemurafenib</title>
          <description>Participants with other BRAF V600-positive tumors were treated with vemurafenib monotherapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="27"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="9"/>
                <participants group_id="P7" count="26"/>
                <participants group_id="P8" count="12"/>
                <participants group_id="P9" count="12"/>
                <participants group_id="P10" count="9"/>
                <participants group_id="P11" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="27"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="9"/>
                <participants group_id="P7" count="26"/>
                <participants group_id="P8" count="12"/>
                <participants group_id="P9" count="12"/>
                <participants group_id="P10" count="9"/>
                <participants group_id="P11" count="28"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="17"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="24"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="9"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat (ITT) population included all participants enrolled in the study irrespective of whether they had received study medication or not.</population>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - Vemurafenib</title>
          <description>Participants with NSCLC were treated with vemurafenib monotherapy.</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2: Ovarian Cancer - Vemurafenib</title>
          <description>Participants with ovarian cancer were treated with vemurafenib monotherapy.</description>
        </group>
        <group group_id="B3">
          <title>Cohort 3a: Colorectal Cancer - Vemurafenib</title>
          <description>Participants with colorectal cancer were treated with vemurafenib monotherapy.</description>
        </group>
        <group group_id="B4">
          <title>Cohort 3b: Colorectal Cancer - Vemurafenib + Cetuximab</title>
          <description>Participants with colorectal cancer were treated with vemurafenib and cetuximab combination therapy.</description>
        </group>
        <group group_id="B5">
          <title>Cohort 4: Cholangiocarcinoma - Vemurafenib</title>
          <description>Participants with cholangiocarcinoma were treated with vemurafenib monotherapy.</description>
        </group>
        <group group_id="B6">
          <title>Cohort 6: Multiple Myeloma - Vemurafenib</title>
          <description>Participants with multiple myeloma were treated with vemurafenib monotherapy.</description>
        </group>
        <group group_id="B7">
          <title>Cohort 7a: ECD/LCH - Vemurafenib</title>
          <description>Participants with Erdheim-Chester disease (ECD) or Langerhans cell histiocytosis (LCH) were treated with vemurafenib monotherapy.</description>
        </group>
        <group group_id="B8">
          <title>Cohort 7b: Anaplastic Thyroid Cancer - Vemurafenib</title>
          <description>Participants with anaplastic thyroid cancer were treated with vemurafenib monotherapy.</description>
        </group>
        <group group_id="B9">
          <title>Cohort 7c: Advanced Stage Astrocytoma - Vemurafenib</title>
          <description>Participants with advanced stage astrocytoma were treated with vemurafenib monotherapy.</description>
        </group>
        <group group_id="B10">
          <title>Cohort 7d: Early Stage Astrocytoma - Vemurafenib</title>
          <description>Participants with early stage astrocytoma were treated with vemurafenib monotherapy.</description>
        </group>
        <group group_id="B11">
          <title>Cohort 7: Other BRAF V600-positive Tumors - Vemurafenib</title>
          <description>Participants with other BRAF V600-positive tumors were treated with vemurafenib monotherapy.</description>
        </group>
        <group group_id="B12">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="62"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="27"/>
            <count group_id="B5" value="9"/>
            <count group_id="B6" value="9"/>
            <count group_id="B7" value="26"/>
            <count group_id="B8" value="12"/>
            <count group_id="B9" value="12"/>
            <count group_id="B10" value="9"/>
            <count group_id="B11" value="28"/>
            <count group_id="B12" value="208"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.4" spread="10.2"/>
                    <measurement group_id="B2" value="45.8" spread="5.3"/>
                    <measurement group_id="B3" value="57.3" spread="5.4"/>
                    <measurement group_id="B4" value="64.3" spread="8.8"/>
                    <measurement group_id="B5" value="53.2" spread="9.7"/>
                    <measurement group_id="B6" value="62.1" spread="4.3"/>
                    <measurement group_id="B7" value="60.8" spread="13.3"/>
                    <measurement group_id="B8" value="66.8" spread="9.2"/>
                    <measurement group_id="B9" value="41.6" spread="12.2"/>
                    <measurement group_id="B10" value="34.3" spread="20.7"/>
                    <measurement group_id="B11" value="53.7" spread="17.5"/>
                    <measurement group_id="B12" value="59.0" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="14"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="8"/>
                    <measurement group_id="B10" value="9"/>
                    <measurement group_id="B11" value="15"/>
                    <measurement group_id="B12" value="111"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="9"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="13"/>
                    <measurement group_id="B12" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Confirmed Best Overall Response Rate (BORR)</title>
        <description>Confirmed BORR: percentage of participants with an objective response (OR) (complete response [CR], partial response [PR], stringent CR [sCR] or very good PR [VGPR]) on 2 occasions &gt;/= 4 weeks apart as assessed by the Investigator using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. or International Myeloma Working Group (IMWG) criteria. RECIST v1.1: CR: disappearance of all target lesions; PR: &gt;/= 30% decrease in the sum of diameters of target lesions. IMWG: CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and &lt;/= 5% plasma cells in bone marrow; PR: &gt;/= 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by &gt;/= 90% or to &lt;200 mg per 24 hours. VGPR: serum and urine M-protein detectable by immunofixation but not on electrophoresis or &gt;/= 90% reduction in serum M-protein plus urine M-protein level &lt; 100 mg per 24 hour; sCR: CR plus normal free light chain (FLC) ratio and no clonal cells in bone marrow.</description>
        <time_frame>Up to approximately 3 years</time_frame>
        <population>ITT population included all participants enrolled in the study irrespective of whether they had received study drug or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - Vemurafenib</title>
            <description>Participants with NSCLC were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Ovarian Cancer - Vemurafenib</title>
            <description>Participants with ovarian cancer were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3a: Colorectal Cancer - Vemurafenib</title>
            <description>Participants with colorectal cancer were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3b: Colorectal Cancer - Vemurafenib + Cetuximab</title>
            <description>Participants with colorectal cancer were treated with vemurafenib and cetuximab combination therapy.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4: Cholangiocarcinoma - Vemurafenib</title>
            <description>Participants with cholangiocarcinoma were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: Multiple Myeloma - Vemurafenib</title>
            <description>Participants with multiple myeloma were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7a: ECD/LCH - Vemurafenib</title>
            <description>Participants with Erdheim-Chester disease (ECD) or Langerhans cell histiocytosis (LCH) were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 7b: Anaplastic Thyroid Cancer - Vemurafenib</title>
            <description>Participants with anaplastic thyroid cancer were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 7c: Advanced Stage Astrocytoma - Vemurafenib</title>
            <description>Participants with advanced stage astrocytoma were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 7d: Early Stage Astrocytoma - Vemurafenib</title>
            <description>Participants with early stage astrocytoma were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O11">
            <title>Cohort 7: Other BRAF V600-positive Tumors - Vemurafenib</title>
            <description>Participants with other BRAF V600-positive tumors were treated with vemurafenib monotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Confirmed Best Overall Response Rate (BORR)</title>
          <description>Confirmed BORR: percentage of participants with an objective response (OR) (complete response [CR], partial response [PR], stringent CR [sCR] or very good PR [VGPR]) on 2 occasions &gt;/= 4 weeks apart as assessed by the Investigator using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. or International Myeloma Working Group (IMWG) criteria. RECIST v1.1: CR: disappearance of all target lesions; PR: &gt;/= 30% decrease in the sum of diameters of target lesions. IMWG: CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and &lt;/= 5% plasma cells in bone marrow; PR: &gt;/= 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by &gt;/= 90% or to &lt;200 mg per 24 hours. VGPR: serum and urine M-protein detectable by immunofixation but not on electrophoresis or &gt;/= 90% reduction in serum M-protein plus urine M-protein level &lt; 100 mg per 24 hour; sCR: CR plus normal free light chain (FLC) ratio and no clonal cells in bone marrow.</description>
          <population>ITT population included all participants enrolled in the study irrespective of whether they had received study drug or not.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="26"/>
                <count group_id="O8" value="12"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="9"/>
                <count group_id="O11" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.1" lower_limit="25.16" upper_limit="50.31"/>
                    <measurement group_id="O2" value="50.0" lower_limit="6.76" upper_limit="93.24"/>
                    <measurement group_id="O3" value="0" lower_limit="0.00" upper_limit="30.85"/>
                    <measurement group_id="O4" value="7.4" lower_limit="0.91" upper_limit="24.29"/>
                    <measurement group_id="O5" value="22.2" lower_limit="2.81" upper_limit="60.01"/>
                    <measurement group_id="O6" value="22.2" lower_limit="2.81" upper_limit="60.01"/>
                    <measurement group_id="O7" value="61.5" lower_limit="40.57" upper_limit="79.77"/>
                    <measurement group_id="O8" value="25.0" lower_limit="5.49" upper_limit="57.19"/>
                    <measurement group_id="O9" value="16.7" lower_limit="2.09" upper_limit="48.41"/>
                    <measurement group_id="O10" value="33.3" lower_limit="7.49" upper_limit="70.07"/>
                    <measurement group_id="O11" value="17.9" lower_limit="6.06" upper_limit="36.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Confirmed Clinical Benefit</title>
        <description>Included were participants with confirmed PR or CR or Stable Disease (SD) that had lasted at least 6 months according to RECIST v1.1 or confirmed CR, PR, VGPR, sCR or SD for at least 6 months according to IMWG criteria. RECIST v1.1: PR: &gt;/= 30% decrease in the sum of diameters of target lesions; CR: disappearance of all target lesions; SD: not meeting criteria for CR, PR or progressive disease (PD). IMWG: CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and &lt;/= 5% plasma cells in bone marrow; PR: &gt;/= 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by &gt;/= 90% or to &lt;200 mg per 24 hours. VGPR: serum and urine M-protein detectable by immunofixation but not on electrophoresis or &gt;/= 90% reduction in serum M-protein plus urine M-protein level &lt; 100 mg per 24 hour; sCR: CR plus normal FLC ratio and no clonal cells in bone marrow; SD: not meeting criteria for CR, VGPR, PR or PD.</description>
        <time_frame>Up to approximately 3 years</time_frame>
        <population>ITT population included all participants enrolled in the study irrespective of whether they had received study medication or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - Vemurafenib</title>
            <description>Participants with NSCLC were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Ovarian Cancer - Vemurafenib</title>
            <description>Participants with ovarian cancer were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3a: Colorectal Cancer - Vemurafenib</title>
            <description>Participants with colorectal cancer were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3b: Colorectal Cancer - Vemurafenib + Cetuximab</title>
            <description>Participants with colorectal cancer were treated with vemurafenib and cetuximab combination therapy.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4: Cholangiocarcinoma - Vemurafenib</title>
            <description>Participants with cholangiocarcinoma were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: Multiple Myeloma - Vemurafenib</title>
            <description>Participants with multiple myeloma were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7a: ECD/LCH - Vemurafenib</title>
            <description>Participants with Erdheim-Chester disease (ECD) or Langerhans cell histiocytosis (LCH) were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 7b: Anaplastic Thyroid Cancer - Vemurafenib</title>
            <description>Participants with anaplastic thyroid cancer were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 7c: Advanced Stage Astrocytoma - Vemurafenib</title>
            <description>Participants with advanced stage astrocytoma were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 7d: Early Stage Astrocytoma - Vemurafenib</title>
            <description>Participants with early stage astrocytoma were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O11">
            <title>Cohort 7: Other BRAF V600-positive Tumors - Vemurafenib</title>
            <description>Participants with other BRAF V600-positive tumors were treated with vemurafenib monotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Confirmed Clinical Benefit</title>
          <description>Included were participants with confirmed PR or CR or Stable Disease (SD) that had lasted at least 6 months according to RECIST v1.1 or confirmed CR, PR, VGPR, sCR or SD for at least 6 months according to IMWG criteria. RECIST v1.1: PR: &gt;/= 30% decrease in the sum of diameters of target lesions; CR: disappearance of all target lesions; SD: not meeting criteria for CR, PR or progressive disease (PD). IMWG: CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and &lt;/= 5% plasma cells in bone marrow; PR: &gt;/= 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by &gt;/= 90% or to &lt;200 mg per 24 hours. VGPR: serum and urine M-protein detectable by immunofixation but not on electrophoresis or &gt;/= 90% reduction in serum M-protein plus urine M-protein level &lt; 100 mg per 24 hour; sCR: CR plus normal FLC ratio and no clonal cells in bone marrow; SD: not meeting criteria for CR, VGPR, PR or PD.</description>
          <population>ITT population included all participants enrolled in the study irrespective of whether they had received study medication or not.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="26"/>
                <count group_id="O8" value="12"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="9"/>
                <count group_id="O11" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.4" lower_limit="35.50" upper_limit="61.44"/>
                    <measurement group_id="O2" value="50.0" lower_limit="6.76" upper_limit="93.24"/>
                    <measurement group_id="O3" value="0">N/A=NE=not estimable, because of insufficient number of participants with events</measurement>
                    <measurement group_id="O4" value="18.5" lower_limit="6.30" upper_limit="38.08"/>
                    <measurement group_id="O5" value="44.4" lower_limit="13.70" upper_limit="78.80"/>
                    <measurement group_id="O6" value="22.2" lower_limit="2.81" upper_limit="60.01"/>
                    <measurement group_id="O7" value="76.9" lower_limit="56.35" upper_limit="91.03"/>
                    <measurement group_id="O8" value="25.0" lower_limit="5.49" upper_limit="57.19"/>
                    <measurement group_id="O9" value="33.3" lower_limit="9.92" upper_limit="65.11"/>
                    <measurement group_id="O10" value="44.4" lower_limit="13.70" upper_limit="78.80"/>
                    <measurement group_id="O11" value="17.9" lower_limit="6.06" upper_limit="36.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate (ORR)</title>
        <description>ORR: percentage of participants with an objective response (OR) (CR, PR, sCR or VGPR) on 2 occasions &gt;/= 4 weeks apart as assessed by the Investigator using RECIST v1.1. or IMWG criteria. RECIST v1.1: CR: disappearance of all target lesions; PR: &gt;/= 30% decrease in the sum of diameters of target lesions. IMWG: CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and &lt;/= 5% plasma cells in bone marrow; PR: &gt;/= 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by &gt;/= 90% or to &lt;200 mg per 24 hours. VGPR: serum and urine M-protein detectable by immunofixation but not on electrophoresis or &gt;/= 90% reduction in serum M-protein plus urine M-protein level &lt; 100 mg per 24 hour; sCR: CR plus normal FLC ratio and no clonal cells in bone marrow.</description>
        <time_frame>Up to approximately 3 years</time_frame>
        <population>ITT population included all participants enrolled in the study irrespective of whether they had received study medication or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - Vemurafenib</title>
            <description>Participants with NSCLC were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Ovarian Cancer - Vemurafenib</title>
            <description>Participants with ovarian cancer were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3a: Colorectal Cancer - Vemurafenib</title>
            <description>Participants with colorectal cancer were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3b: Colorectal Cancer - Vemurafenib + Cetuximab</title>
            <description>Participants with colorectal cancer were treated with vemurafenib and cetuximab combination therapy.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4: Cholangiocarcinoma - Vemurafenib</title>
            <description>Participants with cholangiocarcinoma were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: Multiple Myeloma - Vemurafenib</title>
            <description>Participants with multiple myeloma were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7a: ECD/LCH - Vemurafenib</title>
            <description>Participants with Erdheim-Chester disease (ECD) or Langerhans cell histiocytosis (LCH) were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 7b: Anaplastic Thyroid Cancer - Vemurafenib</title>
            <description>Participants with anaplastic thyroid cancer were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 7c: Advanced Stage Astrocytoma - Vemurafenib</title>
            <description>Participants with advanced stage astrocytoma were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 7d: Early Stage Astrocytoma - Vemurafenib</title>
            <description>Participants with early stage astrocytoma were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O11">
            <title>Cohort 7: Other BRAF V600-positive Tumors - Vemurafenib</title>
            <description>Participants with other BRAF V600-positive tumors were treated with vemurafenib monotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate (ORR)</title>
          <description>ORR: percentage of participants with an objective response (OR) (CR, PR, sCR or VGPR) on 2 occasions &gt;/= 4 weeks apart as assessed by the Investigator using RECIST v1.1. or IMWG criteria. RECIST v1.1: CR: disappearance of all target lesions; PR: &gt;/= 30% decrease in the sum of diameters of target lesions. IMWG: CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and &lt;/= 5% plasma cells in bone marrow; PR: &gt;/= 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by &gt;/= 90% or to &lt;200 mg per 24 hours. VGPR: serum and urine M-protein detectable by immunofixation but not on electrophoresis or &gt;/= 90% reduction in serum M-protein plus urine M-protein level &lt; 100 mg per 24 hour; sCR: CR plus normal FLC ratio and no clonal cells in bone marrow.</description>
          <population>ITT population included all participants enrolled in the study irrespective of whether they had received study medication or not.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="26"/>
                <count group_id="O8" value="12"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="9"/>
                <count group_id="O11" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.00" upper_limit="5.78"/>
                    <measurement group_id="O2" value="0" lower_limit="0.00" upper_limit="60.24"/>
                    <measurement group_id="O3" value="0" lower_limit="0.00" upper_limit="30.85"/>
                    <measurement group_id="O4" value="0" lower_limit="0.00" upper_limit="12.77"/>
                    <measurement group_id="O5" value="0" lower_limit="0.00" upper_limit="33.63"/>
                    <measurement group_id="O6" value="0" lower_limit="0.00" upper_limit="33.63"/>
                    <measurement group_id="O7" value="7.7" lower_limit="0.95" upper_limit="25.13"/>
                    <measurement group_id="O8" value="8.3" lower_limit="0.21" upper_limit="38.48"/>
                    <measurement group_id="O9" value="8.3" lower_limit="0.21" upper_limit="38.48"/>
                    <measurement group_id="O10" value="0" lower_limit="0.00" upper_limit="33.63"/>
                    <measurement group_id="O11" value="3.6" lower_limit="0.09" upper_limit="18.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.1" lower_limit="25.16" upper_limit="50.31"/>
                    <measurement group_id="O2" value="50.0" lower_limit="6.76" upper_limit="93.24"/>
                    <measurement group_id="O3" value="0" lower_limit="0.00" upper_limit="30.85"/>
                    <measurement group_id="O4" value="7.4" lower_limit="0.91" upper_limit="24.29"/>
                    <measurement group_id="O5" value="22.2" lower_limit="2.81" upper_limit="60.01"/>
                    <measurement group_id="O6" value="11.1" lower_limit="0.28" upper_limit="48.25"/>
                    <measurement group_id="O7" value="53.8" lower_limit="33.37" upper_limit="73.41"/>
                    <measurement group_id="O8" value="16.7" lower_limit="2.09" upper_limit="48.41"/>
                    <measurement group_id="O9" value="8.3" lower_limit="0.21" upper_limit="38.48"/>
                    <measurement group_id="O10" value="33.3" lower_limit="7.49" upper_limit="70.07"/>
                    <measurement group_id="O11" value="14.3" lower_limit="4.03" upper_limit="32.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VGPR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">N/A= VGPR data only collected in multiple myeloma cohort</measurement>
                    <measurement group_id="O2" value="NA">N/A= VGPR data only collected in multiple myeloma cohort</measurement>
                    <measurement group_id="O3" value="NA">N/A= VGPR data only collected in multiple myeloma cohort</measurement>
                    <measurement group_id="O4" value="NA">N/A= VGPR data only collected in multiple myeloma cohort</measurement>
                    <measurement group_id="O5" value="NA">N/A= VGPR data only collected in multiple myeloma cohort</measurement>
                    <measurement group_id="O6" value="11.1" lower_limit="0.28" upper_limit="48.25"/>
                    <measurement group_id="O7" value="NA">N/A= VGPR data only collected in multiple myeloma cohort</measurement>
                    <measurement group_id="O8" value="NA">N/A= VGPR data only collected in multiple myeloma cohort</measurement>
                    <measurement group_id="O9" value="NA">N/A= VGPR data only collected in multiple myeloma cohort</measurement>
                    <measurement group_id="O10" value="NA">N/A= VGPR data only collected in multiple myeloma cohort</measurement>
                    <measurement group_id="O11" value="NA">N/A= VGPR data only collected in multiple myeloma cohort</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sCR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">N/A= sCR data only collected in multiple myeloma cohort</measurement>
                    <measurement group_id="O2" value="NA">N/A= sCR data only collected in multiple myeloma cohort</measurement>
                    <measurement group_id="O3" value="NA">N/A= sCR data only collected in multiple myeloma cohort</measurement>
                    <measurement group_id="O4" value="NA">N/A= sCR data only collected in multiple myeloma cohort</measurement>
                    <measurement group_id="O5" value="NA">N/A= sCR data only collected in multiple myeloma cohort</measurement>
                    <measurement group_id="O6" value="0" lower_limit="0.00" upper_limit="33.63"/>
                    <measurement group_id="O7" value="NA">N/A= sCR data only collected in multiple myeloma cohort</measurement>
                    <measurement group_id="O8" value="NA">N/A= sCR data only collected in multiple myeloma cohort</measurement>
                    <measurement group_id="O9" value="NA">N/A= sCR data only collected in multiple myeloma cohort</measurement>
                    <measurement group_id="O10" value="NA">N/A= sCR data only collected in multiple myeloma cohort</measurement>
                    <measurement group_id="O11" value="NA">N/A= sCR data only collected in multiple myeloma cohort</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DOR)</title>
        <description>DOR was defined as the period from the date of initial PR or CR for solid tumors according to RECISTv1.1 and CR, PR, VGPR or sCR for multiple myeloma according to IMWG criteria, until the date of PD or death from any cause. RECIST v1.1: PD: At least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. IMWG: PD: increase of &gt;/= 25% from lowest response value in serum or urine M-protein or bone marrow plasma cell percentage or development of new or increase in size of bone lesions or soft tissue plasmacytomas.</description>
        <time_frame>Up to approximately 3 years</time_frame>
        <population>ITT population included all participants enrolled in the study irrespective of whether they had received study medication or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - Vemurafenib</title>
            <description>Participants with NSCLC were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Ovarian Cancer - Vemurafenib</title>
            <description>Participants with ovarian cancer were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3a: Colorectal Cancer - Vemurafenib</title>
            <description>Participants with colorectal cancer were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3b: Colorectal Cancer - Vemurafenib + Cetuximab</title>
            <description>Participants with colorectal cancer were treated with vemurafenib and cetuximab combination therapy.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4: Cholangiocarcinoma - Vemurafenib</title>
            <description>Participants with cholangiocarcinoma were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: Multiple Myeloma - Vemurafenib</title>
            <description>Participants with multiple myeloma were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7a: ECD/LCH - Vemurafenib</title>
            <description>Participants with Erdheim-Chester disease (ECD) or Langerhans cell histiocytosis (LCH) were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 7b: Anaplastic Thyroid Cancer - Vemurafenib</title>
            <description>Participants with anaplastic thyroid cancer were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 7c: Advanced Stage Astrocytoma - Vemurafenib</title>
            <description>Participants with advanced stage astrocytoma were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 7d: Early Stage Astrocytoma - Vemurafenib</title>
            <description>Participants with early stage astrocytoma were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O11">
            <title>Cohort 7: Other BRAF V600-positive Tumors - Vemurafenib</title>
            <description>Participants with other BRAF V600-positive tumors were treated with vemurafenib monotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DOR)</title>
          <description>DOR was defined as the period from the date of initial PR or CR for solid tumors according to RECISTv1.1 and CR, PR, VGPR or sCR for multiple myeloma according to IMWG criteria, until the date of PD or death from any cause. RECIST v1.1: PD: At least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. IMWG: PD: increase of &gt;/= 25% from lowest response value in serum or urine M-protein or bone marrow plasma cell percentage or development of new or increase in size of bone lesions or soft tissue plasmacytomas.</description>
          <population>ITT population included all participants enrolled in the study irrespective of whether they had received study medication or not.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="26"/>
                <count group_id="O8" value="12"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="9"/>
                <count group_id="O11" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.16" lower_limit="5.49" upper_limit="18.43"/>
                    <measurement group_id="O2" value="8.16" lower_limit="3.88" upper_limit="12.45"/>
                    <measurement group_id="O3" value="NA">N/A=NE=not estimable, because of insufficient number of participants with events</measurement>
                    <measurement group_id="O4" value="6.54" lower_limit="5.68" upper_limit="7.39"/>
                    <measurement group_id="O5" value="12.86" lower_limit="3.58" upper_limit="22.14"/>
                    <measurement group_id="O6" value="NA">N/A=NE=not estimable, because of insufficient number of participants with events</measurement>
                    <measurement group_id="O7" value="NA">N/A=NE=not estimable, because of insufficient number of participants with events</measurement>
                    <measurement group_id="O8" value="9.95" lower_limit="8.31" upper_limit="30.98"/>
                    <measurement group_id="O9" value="NA" lower_limit="13.08">N/A=NE=not estimable, because of insufficient number of participants with events</measurement>
                    <measurement group_id="O10" value="3.42" lower_limit="2.40" upper_limit="7.49"/>
                    <measurement group_id="O11" value="9.92" lower_limit="3.48" upper_limit="21.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Response</title>
        <description>Time to response was defined as the time from the first day of study treatment to the date of first CR, or PR for solid tumors according to RECISTv1.1 and CR, PR, VGPR or sCR for multiple myeloma according to IMWG criteria. RECIST v1.1: CR: disappearance of all target lesions; PR: at least a 30% decrease in the sum of diameters of target lesions. IMWG criteria: CR: negative immunofixation on serum and urine and disappearance of any soft tissue plasmacytomas and &lt;/= 5% plasma cells in bone marrow; PR: &gt;/= 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by &gt;/= 90% or to &lt; 200 mg per 24 hours. VGPR: serum and urine M-protein detectable by immunofixation but not on electrophoresis or &gt;/= 90% reduction in serum M-protein plus urine M-protein level &lt; 100 mg per 24 hour; sCR: CR plus normal FLC ratio and no clonal cells in bone marrow.</description>
        <time_frame>Up to approximately 3 years</time_frame>
        <population>ITT population included all participants enrolled in the study irrespective of whether they had received study medication or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - Vemurafenib</title>
            <description>Participants with NSCLC were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Ovarian Cancer - Vemurafenib</title>
            <description>Participants with ovarian cancer were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3a: Colorectal Cancer - Vemurafenib</title>
            <description>Participants with colorectal cancer were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3b: Colorectal Cancer - Vemurafenib + Cetuximab</title>
            <description>Participants with colorectal cancer were treated with vemurafenib and cetuximab combination therapy.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4: Cholangiocarcinoma - Vemurafenib</title>
            <description>Participants with cholangiocarcinoma were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: Multiple Myeloma - Vemurafenib</title>
            <description>Participants with multiple myeloma were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7a: ECD/LCH - Vemurafenib</title>
            <description>Participants with Erdheim-Chester disease (ECD) or Langerhans cell histiocytosis (LCH) were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 7b: Anaplastic Thyroid Cancer - Vemurafenib</title>
            <description>Participants with anaplastic thyroid cancer were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 7c: Advanced Stage Astrocytoma - Vemurafenib</title>
            <description>Participants with advanced stage astrocytoma were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 7d: Early Stage Astrocytoma - Vemurafenib</title>
            <description>Participants with early stage astrocytoma were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O11">
            <title>Cohort 7: Other BRAF V600-positive Tumors - Vemurafenib</title>
            <description>Participants with other BRAF V600-positive tumors were treated with vemurafenib monotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Response</title>
          <description>Time to response was defined as the time from the first day of study treatment to the date of first CR, or PR for solid tumors according to RECISTv1.1 and CR, PR, VGPR or sCR for multiple myeloma according to IMWG criteria. RECIST v1.1: CR: disappearance of all target lesions; PR: at least a 30% decrease in the sum of diameters of target lesions. IMWG criteria: CR: negative immunofixation on serum and urine and disappearance of any soft tissue plasmacytomas and &lt;/= 5% plasma cells in bone marrow; PR: &gt;/= 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by &gt;/= 90% or to &lt; 200 mg per 24 hours. VGPR: serum and urine M-protein detectable by immunofixation but not on electrophoresis or &gt;/= 90% reduction in serum M-protein plus urine M-protein level &lt; 100 mg per 24 hour; sCR: CR plus normal FLC ratio and no clonal cells in bone marrow.</description>
          <population>ITT population included all participants enrolled in the study irrespective of whether they had received study medication or not.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="26"/>
                <count group_id="O8" value="12"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="9"/>
                <count group_id="O11" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.26" lower_limit="3.68">N/A=NE=not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="1.64">N/A=NE=not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O3" value="NA">N/A=NE=not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O4" value="NA">N/A=NE=not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="3.52">N/A=NE=not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O6" value="5.75">N/A=NE=not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O7" value="5.49" lower_limit="3.68" upper_limit="13.73"/>
                    <measurement group_id="O8" value="NA" lower_limit="1.68">N/A=NE=not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O9" value="NA" lower_limit="1.74">N/A=NE=not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O10" value="NA" lower_limit="2.33">N/A=NE=not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O11" value="NA" lower_limit="3.68">N/A=NE=not estimable due to insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Tumor Progression (TTP)</title>
        <description>TTP was defined as time from the first day of study treatment to the first occurrence of progressive disease (PD). RECIST v1.1: PD: at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. IMWG: PD: increase of &gt;/= 25% from lowest response value in serum or urine M-protein or bone marrow plasma cell percentage or development of new or increase in size of bone lesions or soft tissue plasmacytomas.</description>
        <time_frame>Up to approximately 3 years</time_frame>
        <population>ITT population included all participants enrolled in the study irrespective of whether they had received study medication or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - Vemurafenib</title>
            <description>Participants with NSCLC were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Ovarian Cancer - Vemurafenib</title>
            <description>Participants with ovarian cancer were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3a: Colorectal Cancer - Vemurafenib</title>
            <description>Participants with colorectal cancer were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3b: Colorectal Cancer - Vemurafenib + Cetuximab</title>
            <description>Participants with colorectal cancer were treated with vemurafenib and cetuximab combination therapy.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4: Cholangiocarcinoma - Vemurafenib</title>
            <description>Participants with cholangiocarcinoma were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: Multiple Myeloma - Vemurafenib</title>
            <description>Participants with multiple myeloma were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7a: ECD/LCH - Vemurafenib</title>
            <description>Participants with Erdheim-Chester disease (ECD) or Langerhans cell histiocytosis (LCH) were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 7b: Anaplastic Thyroid Cancer - Vemurafenib</title>
            <description>Participants with anaplastic thyroid cancer were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 7c: Advanced Stage Astrocytoma - Vemurafenib</title>
            <description>Participants with advanced stage astrocytoma were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 7d: Early Stage Astrocytoma - Vemurafenib</title>
            <description>Participants with early stage astrocytoma were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O11">
            <title>Cohort 7: Other BRAF V600-positive Tumors - Vemurafenib</title>
            <description>Participants with other BRAF V600-positive tumors were treated with vemurafenib monotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Tumor Progression (TTP)</title>
          <description>TTP was defined as time from the first day of study treatment to the first occurrence of progressive disease (PD). RECIST v1.1: PD: at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. IMWG: PD: increase of &gt;/= 25% from lowest response value in serum or urine M-protein or bone marrow plasma cell percentage or development of new or increase in size of bone lesions or soft tissue plasmacytomas.</description>
          <population>ITT population included all participants enrolled in the study irrespective of whether they had received study medication or not.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="26"/>
                <count group_id="O8" value="12"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="9"/>
                <count group_id="O11" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.33" lower_limit="5.29" upper_limit="9.66"/>
                    <measurement group_id="O2" value="6.44" lower_limit="1.87" upper_limit="14.29"/>
                    <measurement group_id="O3" value="3.88" lower_limit="1.84" upper_limit="5.52"/>
                    <measurement group_id="O4" value="3.68" lower_limit="3.45" upper_limit="5.39"/>
                    <measurement group_id="O5" value="3.02" lower_limit="1.64" upper_limit="9.00"/>
                    <measurement group_id="O6" value="4.63" lower_limit="2.89">N/A=NE=not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O7" value="NA">N/A=NE=not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O8" value="2.83" lower_limit="1.77" upper_limit="5.49"/>
                    <measurement group_id="O9" value="5.62" lower_limit="1.81" upper_limit="14.85"/>
                    <measurement group_id="O10" value="5.36" lower_limit="3.02" upper_limit="9.10"/>
                    <measurement group_id="O11" value="3.65" lower_limit="1.68" upper_limit="5.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (PFS)</title>
        <description>PFS was defined as the time from the first day of study treatment, until the first documented PD or death from any cause, whichever occurs first. RECIST v1.1: PD: at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. IMWG criteria: PD: increase of &gt;/= 25% from lowest response value in serum or urine M-protein or bone marrow plasma cell percentage or development of new or increase in size of bone lesions or soft tissue plasmacytomas.</description>
        <time_frame>Up to approximately 3 years</time_frame>
        <population>ITT population included all participants enrolled in the study irrespective of whether they had received study medication or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - Vemurafenib</title>
            <description>Participants with NSCLC were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Ovarian Cancer - Vemurafenib</title>
            <description>Participants with ovarian cancer were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3a: Colorectal Cancer - Vemurafenib</title>
            <description>Participants with colorectal cancer were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3b: Colorectal Cancer - Vemurafenib + Cetuximab</title>
            <description>Participants with colorectal cancer were treated with vemurafenib and cetuximab combination therapy.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4: Cholangiocarcinoma - Vemurafenib</title>
            <description>Participants with cholangiocarcinoma were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: Multiple Myeloma - Vemurafenib</title>
            <description>Participants with multiple myeloma were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7a: ECD/LCH - Vemurafenib</title>
            <description>Participants with Erdheim-Chester disease (ECD) or Langerhans cell histiocytosis (LCH) were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 7b: Anaplastic Thyroid Cancer - Vemurafenib</title>
            <description>Participants with anaplastic thyroid cancer were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 7c: Advanced Stage Astrocytoma - Vemurafenib</title>
            <description>Participants with advanced stage astrocytoma were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 7d: Early Stage Astrocytoma - Vemurafenib</title>
            <description>Participants with early stage astrocytoma were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O11">
            <title>Cohort 7: Other BRAF V600-positive Tumors - Vemurafenib</title>
            <description>Participants with other BRAF V600-positive tumors were treated with vemurafenib monotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS)</title>
          <description>PFS was defined as the time from the first day of study treatment, until the first documented PD or death from any cause, whichever occurs first. RECIST v1.1: PD: at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. IMWG criteria: PD: increase of &gt;/= 25% from lowest response value in serum or urine M-protein or bone marrow plasma cell percentage or development of new or increase in size of bone lesions or soft tissue plasmacytomas.</description>
          <population>ITT population included all participants enrolled in the study irrespective of whether they had received study medication or not.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="26"/>
                <count group_id="O8" value="12"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="9"/>
                <count group_id="O11" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.51" lower_limit="5.16" upper_limit="8.97"/>
                    <measurement group_id="O2" value="6.44" lower_limit="1.87" upper_limit="14.29"/>
                    <measurement group_id="O3" value="3.88" lower_limit="1.84" upper_limit="5.52"/>
                    <measurement group_id="O4" value="3.68" lower_limit="1.81" upper_limit="5.39"/>
                    <measurement group_id="O5" value="3.02" lower_limit="1.64" upper_limit="9.00"/>
                    <measurement group_id="O6" value="4.63" lower_limit="2.89">N/A=NE=not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O7" value="NA">N/A=NE=not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O8" value="2.83" lower_limit="1.77" upper_limit="5.49"/>
                    <measurement group_id="O9" value="9.59" lower_limit="1.81" upper_limit="14.78"/>
                    <measurement group_id="O10" value="5.26" lower_limit="3.02" upper_limit="5.72"/>
                    <measurement group_id="O11" value="3.12" lower_limit="1.64" upper_limit="5.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>OS was defined as time between the first day of study treatment and date of death of any cause.</description>
        <time_frame>Up to approximately 3 years</time_frame>
        <population>ITT population included all participants enrolled in the study irrespective of whether they had received study medication or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - Vemurafenib</title>
            <description>Participants with NSCLC were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Ovarian Cancer - Vemurafenib</title>
            <description>Participants with ovarian cancer were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3a: Colorectal Cancer - Vemurafenib</title>
            <description>Participants with colorectal cancer were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3b: Colorectal Cancer - Vemurafenib + Cetuximab</title>
            <description>Participants with colorectal cancer were treated with vemurafenib and cetuximab combination therapy.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4: Cholangiocarcinoma - Vemurafenib</title>
            <description>Participants with cholangiocarcinoma were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: Multiple Myeloma - Vemurafenib</title>
            <description>Participants with multiple myeloma were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7a: ECD/LCH - Vemurafenib</title>
            <description>Participants with Erdheim-Chester disease (ECD) or Langerhans cell histiocytosis (LCH) were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 7b: Anaplastic Thyroid Cancer - Vemurafenib</title>
            <description>Participants with anaplastic thyroid cancer were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 7c: Advanced Stage Astrocytoma - Vemurafenib</title>
            <description>Participants with advanced stage astrocytoma were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 7d: Early Stage Astrocytoma - Vemurafenib</title>
            <description>Participants with early stage astrocytoma were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O11">
            <title>Cohort 7: Other BRAF V600-positive Tumors - Vemurafenib</title>
            <description>Participants with other BRAF V600-positive tumors were treated with vemurafenib monotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>OS was defined as time between the first day of study treatment and date of death of any cause.</description>
          <population>ITT population included all participants enrolled in the study irrespective of whether they had received study medication or not.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="26"/>
                <count group_id="O8" value="12"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="9"/>
                <count group_id="O11" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.38" lower_limit="9.56" upper_limit="22.77"/>
                    <measurement group_id="O2" value="NA" lower_limit="2.56">N/A=NE=not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O3" value="9.30" lower_limit="7.82" upper_limit="12.88"/>
                    <measurement group_id="O4" value="7.16" lower_limit="5.49" upper_limit="11.73"/>
                    <measurement group_id="O5" value="17.94" lower_limit="11.20">N/A=NE=not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O6" value="24.54" lower_limit="4.96">N/A=NE=not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O7" value="NA">N/A=NE=not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O8" value="5.88" lower_limit="2.17" upper_limit="16.79"/>
                    <measurement group_id="O9" value="40.11" lower_limit="9.59" upper_limit="40.11"/>
                    <measurement group_id="O10" value="12.75" lower_limit="6.70">N/A=NE=not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O11" value="11.56" lower_limit="3.71" upper_limit="28.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Tolerated Dose for Vemurafenib in Combination With Cetuximab</title>
        <description>Cohort 3b included participants with colorectal cancer treated with escalating doses of vemurafenib and cetuximab. The escalating doses were as follows: Dose Level 1: 720 milligrams (mg) of vemurafenib orally twice daily starting on Day 2 of Cycle 1 and 300 milligrams per square meter (mg/m^2) loading dose of cetuximab by infusion and then 200 mg/m^2 weekly; Dose Level 2: 720 mg of vemurafenib twice daily starting on Day 2 of Cycle 1 and 400 mg/m^2 loading dose of cetuximab and then 250 mg/m^2 weekly; Dose Level 3: 960 mg of vemurafenib twice daily starting on Day 2 of Cycle 1 and 400 mg/m^2 loading dose of cetuximab and then 250 mg/m^2 weekly. Reported here are the maximum tolerated doses for each vemurafenib and cetuximab.</description>
        <time_frame>Up to approximately 3 years</time_frame>
        <population>All participants from Cohort 3b who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - Vemurafenib</title>
            <description>Participants with NSCLC were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Ovarian Cancer - Vemurafenib</title>
            <description>Participants with ovarian cancer were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3a: Colorectal Cancer - Vemurafenib</title>
            <description>Participants with colorectal cancer were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3b: Colorectal Cancer - Vemurafenib + Cetuximab</title>
            <description>Participants with colorectal cancer were treated with vemurafenib and cetuximab combination therapy.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4: Cholangiocarcinoma - Vemurafenib</title>
            <description>Participants with cholangiocarcinoma were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: Multiple Myeloma - Vemurafenib</title>
            <description>Participants with multiple myeloma were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7a: ECD/LCH - Vemurafenib</title>
            <description>Participants with Erdheim-Chester disease (ECD) or Langerhans cell histiocytosis (LCH) were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 7b: Anaplastic Thyroid Cancer - Vemurafenib</title>
            <description>Participants with anaplastic thyroid cancer were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 7c: Advanced Stage Astrocytoma - Vemurafenib</title>
            <description>Participants with advanced stage astrocytoma were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 7d: Early Stage Astrocytoma - Vemurafenib</title>
            <description>Participants with early stage astrocytoma were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O11">
            <title>Cohort 7: Other BRAF V600-positive Tumors - Vemurafenib</title>
            <description>Participants with other BRAF V600-positive tumors were treated with vemurafenib monotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose for Vemurafenib in Combination With Cetuximab</title>
          <description>Cohort 3b included participants with colorectal cancer treated with escalating doses of vemurafenib and cetuximab. The escalating doses were as follows: Dose Level 1: 720 milligrams (mg) of vemurafenib orally twice daily starting on Day 2 of Cycle 1 and 300 milligrams per square meter (mg/m^2) loading dose of cetuximab by infusion and then 200 mg/m^2 weekly; Dose Level 2: 720 mg of vemurafenib twice daily starting on Day 2 of Cycle 1 and 400 mg/m^2 loading dose of cetuximab and then 250 mg/m^2 weekly; Dose Level 3: 960 mg of vemurafenib twice daily starting on Day 2 of Cycle 1 and 400 mg/m^2 loading dose of cetuximab and then 250 mg/m^2 weekly. Reported here are the maximum tolerated doses for each vemurafenib and cetuximab.</description>
          <population>All participants from Cohort 3b who received at least one dose of study medication.</population>
          <units>milligrams (mg)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>vemurafenib</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="960"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cetuximab</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Dose-limiting Toxicities of Vemurafenib in Combination With Cetuximab</title>
        <description>Cohort 3b included participants with colorectal cancer treated with escalating doses of vemurafenib and cetuximab. The escalating doses were as follows: Dose Level 1: 720 milligrams (mg) of vemurafenib orally twice daily starting on Day 2 of Cycle 1 and 300 milligrams per square meter (mg/m^2) loading dose of cetuximab by infusion and then 200 mg/m^2 weekly; Dose Level 2: 720 mg of vemurafenib twice daily starting on Day 2 of Cycle 1 and 400 mg/m^2 loading dose of cetuximab and then 250 mg/m^2 weekly; Dose Level 3: 960 mg of vemurafenib twice daily starting on Day 2 of Cycle 1 and 400 mg/m^2 loading dose of cetuximab and then 250 mg/m^2 weekly. Reported here are type and number of dose limited toxicities observed.</description>
        <time_frame>Up to 28 days</time_frame>
        <population>All participants from Cohort 3b who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - Vemurafenib</title>
            <description>Participants with NSCLC were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Ovarian Cancer - Vemurafenib</title>
            <description>Participants with ovarian cancer were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3a: Colorectal Cancer - Vemurafenib</title>
            <description>Participants with colorectal cancer were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3b: Colorectal Cancer - Vemurafenib + Cetuximab</title>
            <description>Participants with colorectal cancer were treated with vemurafenib and cetuximab combination therapy.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4: Cholangiocarcinoma - Vemurafenib</title>
            <description>Participants with cholangiocarcinoma were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: Multiple Myeloma - Vemurafenib</title>
            <description>Participants with multiple myeloma were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7a: ECD/LCH - Vemurafenib</title>
            <description>Participants with Erdheim-Chester disease (ECD) or Langerhans cell histiocytosis (LCH) were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 7b: Anaplastic Thyroid Cancer - Vemurafenib</title>
            <description>Participants with anaplastic thyroid cancer were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 7c: Advanced Stage Astrocytoma - Vemurafenib</title>
            <description>Participants with advanced stage astrocytoma were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 7d: Early Stage Astrocytoma - Vemurafenib</title>
            <description>Participants with early stage astrocytoma were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O11">
            <title>Cohort 7: Other BRAF V600-positive Tumors - Vemurafenib</title>
            <description>Participants with other BRAF V600-positive tumors were treated with vemurafenib monotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Dose-limiting Toxicities of Vemurafenib in Combination With Cetuximab</title>
          <description>Cohort 3b included participants with colorectal cancer treated with escalating doses of vemurafenib and cetuximab. The escalating doses were as follows: Dose Level 1: 720 milligrams (mg) of vemurafenib orally twice daily starting on Day 2 of Cycle 1 and 300 milligrams per square meter (mg/m^2) loading dose of cetuximab by infusion and then 200 mg/m^2 weekly; Dose Level 2: 720 mg of vemurafenib twice daily starting on Day 2 of Cycle 1 and 400 mg/m^2 loading dose of cetuximab and then 250 mg/m^2 weekly; Dose Level 3: 960 mg of vemurafenib twice daily starting on Day 2 of Cycle 1 and 400 mg/m^2 loading dose of cetuximab and then 250 mg/m^2 weekly. Reported here are type and number of dose limited toxicities observed.</description>
          <population>All participants from Cohort 3b who received at least one dose of study medication.</population>
          <units>dose-limiting toxicities</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 3 amylase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4 lipase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety: Percentage of Participants With Adverse Event</title>
        <description>An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.</description>
        <time_frame>Up to approximately 3 years</time_frame>
        <population>The safety population included all participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - Vemurafenib</title>
            <description>Participants with NSCLC were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Ovarian Cancer - Vemurafenib</title>
            <description>Participants with ovarian cancer were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3a: Colorectal Cancer - Vemurafenib</title>
            <description>Participants with colorectal cancer were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3b: Colorectal Cancer - Vemurafenib + Cetuximab</title>
            <description>Participants with colorectal cancer were treated with vemurafenib and cetuximab combination therapy.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4: Cholangiocarcinoma - Vemurafenib</title>
            <description>Participants with cholangiocarcinoma were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: Multiple Myeloma - Vemurafenib</title>
            <description>Participants with multiple myeloma were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7a: ECD/LCH - Vemurafenib</title>
            <description>Participants with Erdheim-Chester disease (ECD) or Langerhans cell histiocytosis (LCH) were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 7b: Anaplastic Thyroid Cancer - Vemurafenib</title>
            <description>Participants with anaplastic thyroid cancer were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 7c: Advanced Stage Astrocytoma - Vemurafenib</title>
            <description>Participants with advanced stage astrocytoma were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 7d: Early Stage Astrocytoma - Vemurafenib</title>
            <description>Participants with early stage astrocytoma were treated with vemurafenib monotherapy.</description>
          </group>
          <group group_id="O11">
            <title>Cohort 7: Other BRAF V600-positive Tumors - Vemurafenib</title>
            <description>Participants with other BRAF V600-positive tumors were treated with vemurafenib monotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Percentage of Participants With Adverse Event</title>
          <description>An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.</description>
          <population>The safety population included all participants who received at least one dose of study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="26"/>
                <count group_id="O8" value="12"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="9"/>
                <count group_id="O11" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="100"/>
                    <measurement group_id="O5" value="100"/>
                    <measurement group_id="O6" value="100"/>
                    <measurement group_id="O7" value="100"/>
                    <measurement group_id="O8" value="91.7"/>
                    <measurement group_id="O9" value="100"/>
                    <measurement group_id="O10" value="100"/>
                    <measurement group_id="O11" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From baseline up to approximately 3 years</time_frame>
      <desc>The safety population included all participants who received at least one dose of study medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort 3b: Colorectal Cancer - Vemurafenib + Cetuximab</title>
          <description>Participants with colorectal cancer were treated with vemurafenib and cetuximab combination therapy.</description>
        </group>
        <group group_id="E2">
          <title>Pooled Arm - Vemurafenib</title>
          <description>Participants with a variety of cancer types, who were treated with vemurafenib monotherapy, were combined into this arm.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Pseudolymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Splenic infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Dressler's syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Iridocyclitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Duodenal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Glucose tolerance impaired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Keratoacanthoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Chronic myelomonocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Paraganglion neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Posterior reversible encephalopathy syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Bladder dilatation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Obstructive uropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Laryngeal dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acute febrile neutrophilic dermatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Jugular vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="177" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Xerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acrochordon</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Papilloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Micturition urgency</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Dermatitis bullous</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Skin fissures</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Toxic skin eruption</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Keratosis pilaris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Milia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Papule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-La Roche</organization>
      <phone>800 821-8590</phone>
      <email>genentech@druginfo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

